Inhalation Delivery of Exosome and microRNA Therapy for Lung Fibrosis
吸入外泌体和 microRNA 治疗肺纤维化
基本信息
- 批准号:10643908
- 负责人:
- 金额:$ 36.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-15 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AllogenicApoptosisAutologousBleomycinCOVID-19/ARDSCell CommunicationCell TherapyCell TransplantationCell secretionCellsCicatrixClinicalClinical TrialsConnective TissueCoupledDataDevelopmentDiagnosisDiseaseDisease ProgressionDisease modelDoseDown-RegulationElectroporationFaceFibroblastsFibrosisFutureGene ExpressionGene Expression ProfilingGenesGenomic approachInfiltrationInfusion proceduresInhalationLabelLungLung TransplantationMacrophageMapsMediatingMediatorMicroRNAsModelingMolecularMolecular TargetNanostructuresOntologyPathway AnalysisPathway interactionsPatientsPlayPopulationProcessPulmonary FibrosisRattusRecombinant ProteinsRecoveryRegenerative MedicineResolutionRiskRodent ModelRoleRouteSafetySeveritiesSeverity of illnessSmall Interfering RNASourceSurvival RateTGF Beta Signaling PathwayTestingTherapeuticTherapeutic EffectTransforming Growth Factor betaTumorigenicityVesicleVisualizationWorkadult stem cellantifibrotic treatmentcell typecellular targetingclinical translationcurative treatmentsdifferential expressionengineered exosomesexosomeextracellular vesiclesfibrotic lungfirst-in-humanidiopathic pulmonary fibrosisimmunogenicityin vivoinhibitorknock-downloss of functionlung injurylung repairnon-geneticnovelnovel therapeutic interventionpreclinical efficacypreclinical safetypreservationpulmonary functionregenerativerepairedresponsesingle cell sequencingsingle-cell RNA sequencingstem cell exosomesstem cell therapystem cellstissue repairuptake
项目摘要
PROJECT ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is an ultimately fatal disease whose only curative treatment is lung
transplant. IPF is characterized by formation of fibrotic lesions in the lung, eventually resulting in
scarring and progressive loss of lung function. Despite some newer treatments, IPF patients still have
a median survival rate of only 3-5 years once diagnosed. Clearly, new therapeutic approaches are
needed to treat this devastating disease. A promising avenue of approach is stem cell therapy. In the
past 8 years, our lab has been developing lung spheroid cells (LSCs) as a novel source of therapeutic
lung cells, and FDA approval of clinical trials with LSC treatment of patients with IPF are being pursued.
Nonetheless, stem cell-based therapy faces several important limitations. Live cells need to be
carefully preserved and processed before usage, and cell transplantation carries certain
immunogenicity and tumorigenicity risks. Importantly, live stem cells cannot be delivered to the lung
via inhalation, which is the most convenient and effective route to deliver therapeutics to the lung.
Recently, we and others have made the novel and exciting observation that many adult stem cells
exert their beneficial effects mainly through secretion of regenerative factors that go on to promote
endogenous repair. In the preliminary studies that form the basis for this application, we have
discovered that secretions from cultured LSCs are just as, if not more, effective than the LSCs
themselves in attenuating and resolving IPF in rodent models of the disease. In the quest for active
components in the LSC secretions, we found that LSCs secrete large numbers of exosomes (30-150
nm vesicles secreted by numerous cell types). We have shown that exosomes derived from LSCs
(LSC-Exo) are therapeutic and regenerative to the injured lung, suggesting these nanostructures are
largely responsible for the reparative response to LSC secretions in rodent models of IPF. It is known
that exosomes carry microRNAs (miRs) cargoes that could play important roles in cell-cell
communication and tissue repair, and indeed we found that LSC-Exo are highly enriched with miR-
30a and Let-7. In this proposed study, we plan to determine safety and efficacy as well as medium
effective dose of LSC-Exo required for lung repair in rodent models of IPF, to determine the major
recipient cells of LSC-Exo in the lung, and determine that the relevant molecular target(s) of exosomal
mediated repair and recovery. We hypothesize that key miRs withing LSC-Exo such as miR-30a and
Let-7 are mediators of the TGF-beta signaling pathway, using the data produced by scRNA-Seq we
will finally determine whether further miR enrichment in these exosomes achieves optimal lung repair.
The development of cell-free or non-living therapeutics derived from stem cells has the potential to
revolutionize current regenerative medicine practice.
项目摘要
特发性肺纤维化(IPF)是一种最终致命的疾病,其唯一的治愈性治疗是肺
移植IPF的特征在于肺纤维化病变的形成,最终导致
疤痕和肺功能的逐渐丧失。尽管有一些较新的治疗方法,IPF患者仍有
一旦确诊,中位生存率仅为3-5年。显然,新的治疗方法
来治疗这种毁灭性的疾病干细胞治疗是一种很有前途的方法。在
在过去的8年里,我们的实验室一直在开发肺球状体细胞(LSC)作为一种新的治疗来源,
LSC治疗IPF患者的临床试验正在寻求FDA批准。
尽管如此,基于干细胞的治疗仍面临几个重要的局限性。活细胞需要
在使用前仔细保存和处理,细胞移植携带一定的
免疫原性和致瘤性风险。重要的是,活的干细胞不能被输送到肺部,
通过吸入,这是将治疗剂递送到肺的最方便和有效的途径。
最近,我们和其他人发现了一个新奇而令人兴奋的现象,
发挥其有益的影响,主要是通过分泌再生因子,继续促进
内源性修复在构成本申请基础的初步研究中,我们
发现培养的LSC的分泌物与LSC一样有效,甚至更有效
在疾病的啮齿动物模型中减轻和解决IPF。在寻求积极的
在LSC分泌物中的组分中,我们发现LSC分泌大量的外泌体(30-150
由许多细胞类型分泌的nm囊泡)。我们已经表明,来源于LSC的外泌体
(LSC-Exo)对受伤的肺具有治疗性和再生性,这表明这些纳米结构是
在啮齿动物IPF模型中,主要负责对LSC分泌物的修复反应。已知
外泌体携带微小RNA(miRs)货物,在细胞间相互作用中发挥重要作用,
通讯和组织修复,事实上,我们发现LSC-Exo高度富集miR-
30 a和Let-7。在这项拟议的研究中,我们计划确定安全性和有效性以及中等剂量
在IPF啮齿动物模型中肺修复所需的LSC-Exo的有效剂量,以确定
肺中LSC-Exo的受体细胞,并确定外泌体的相关分子靶标
介导的修复和恢复。我们假设LSC-Exo中的关键miRs,如miR-30 a和miR-30 b,
Let-7是TGF-β信号通路的介质,使用scRNA-Seq产生的数据,我们
将最终确定这些外泌体中的进一步miR富集是否实现最佳的肺修复。
来源于干细胞的无细胞或无生命治疗剂的开发具有潜力,
彻底改变目前的再生医学实践。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Phuong-Uyen C Dinh其他文献
Phuong-Uyen C Dinh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Phuong-Uyen C Dinh', 18)}}的其他基金
Inhalation Delivery of Exosome and microRNA Therapy for Lung Fibrosis
吸入外泌体和 microRNA 治疗肺纤维化
- 批准号:
10502817 - 财政年份:2022
- 资助金额:
$ 36.98万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 36.98万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 36.98万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 36.98万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 36.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 36.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 36.98万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 36.98万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 36.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 36.98万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 36.98万 - 项目类别:
Discovery Grants Program - Individual